Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dexcom Inc (DXCM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dexcom Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1093557.
Total stock buying since 2014: $1,746,350.
Total stock sales since 2014: $785,755,539.
Total stock option exercises since 2014: $16,751,908.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 177,442 | $13,869,196 | 0 | $0 |
| 2024 | 0 | $0 | 290,565 | $37,445,869 | 0 | $0 |
| 2023 | 0 | $0 | 239,577 | $27,218,371 | 0 | $0 |
| 2022 | 0 | $0 | 76,614 | $22,696,065 | 0 | $0 |
| 2021 | 0 | $0 | 299,457 | $128,341,957 | 0 | $0 |
| 2020 | 0 | $0 | 438,604 | $143,140,207 | 20,385 | $199,543 |
| 2019 | 0 | $0 | 427,888 | $64,727,520 | 30,603 | $153,065 |
| 2018 | 0 | $0 | 576,502 | $64,666,028 | 197,834 | $1,158,125 |
| 2017 | 35,000 | $1,746,350 | 364,657 | $27,002,321 | 208,503 | $1,718,699 |
| 2016 | 0 | $0 | 1,234,804 | $98,963,335 | 387,003 | $2,212,500 |
| 2015 | 0 | $0 | 2,059,653 | $157,458,815 | 1,352,001 | $11,309,976 |
| 2014 | 0 | $0 | 7,500 | $225,855 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-09-10 | Leach Jacob Steven (SVP, Research & Development) | Sale | 4,614 | 143.75 | 663,285 |
| 2018-09-10 | Murphy Patrick Michael (VP, Legal Aff & Chf Compl Ofcr) | Sale | 2,372 | 143.62 | 340,666 |
| 2018-09-10 | Blackford Quentin S. (EVP, CFO, PFO & PAO) | Sale | 7,149 | 143.75 | 1,027,704 |
| 2018-09-10 | Ace Heather S (SVP Human Resources) | Sale | 1,832 | 143.75 | 263,359 |
| 2018-09-10 | Abbey Donald (EVP, Quality & Regulatory Afrs) | Sale | 2,303 | 143.75 | 331,067 |
| 2018-09-10 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 5,483 | 143.75 | 788,208 |
| 2018-09-10 | Moy Jeffrey (SVP, Operations) | Sale | 10,330 | 143.62 | 1,483,594 |
| 2018-09-10 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 5,483 | 143.75 | 788,208 |
| 2018-09-10 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 5,587 | 143.75 | 803,159 |
| 2018-09-10 | Sayer Kevin R (President, CEO & Chairman) | Sale | 25,495 | 143.44 | 3,657,079 |
| 2018-09-10 | Sayer Kevin R (President, CEO & Chairman) | Option Ex | 11,161 | 4.58 | 51,117 |
| 2018-08-24 | Leach Jacob Steven (SVP, Research & Development) | Sale | 20,577 | 138.32 | 2,846,148 |
| 2018-08-24 | Leach Jacob Steven (SVP, Research & Development) | Option Ex | 20,577 | 4.55 | 93,728 |
| 2018-08-24 | Foletta Mark G (Director) | Sale | 1,000 | 137.50 | 137,503 |
| 2018-08-24 | Altman Steven R (Director) | Sale | 5,000 | 136.47 | 682,360 |
| 2018-08-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,584 | 141.11 | 364,638 |
| 2018-08-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 3,114 | 141.10 | 439,382 |
| 2018-08-14 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 5,000 | 124.56 | 622,805 |
| 2018-08-13 | Sayer Kevin R (President, CEO & Chairman) | Sale | 11,161 | 123.43 | 1,377,613 |
| 2018-08-13 | Sayer Kevin R (President, CEO & Chairman) | Option Ex | 11,161 | 4.58 | 51,117 |
| 2018-08-10 | Murphy Patrick Michael (VP, Legal Aff & Chf Compl Ofcr) | Sale | 12,500 | 123.74 | 1,546,750 |
| 2018-08-06 | Augustinos Nicholas (Director) | Sale | 12,300 | 121.47 | 1,494,031 |
| 2018-08-01 | Moy Jeffrey (SVP, Operations) | Sale | 5,831 | 94.13 | 548,872 |
| 2018-07-25 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 3,114 | 101.94 | 317,428 |
| 2018-07-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,581 | 102.81 | 265,347 |
| 2018-07-16 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 5,000 | 99.92 | 499,590 |
| 2018-07-16 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 99.94 | 999,440 |
| 2018-07-09 | Sayer Kevin R (President & CEO) | Sale | 14,219 | 99.86 | 1,419,909 |
| 2018-06-28 | Moy Jeffrey (SVP, Operations) | Sale | 59,193 | 92.29 | 5,462,744 |
| 2018-06-25 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,581 | 98.58 | 254,432 |
| 2018-06-15 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 97.81 | 978,100 |
| 2018-06-12 | Topol Eric (Director) | Sale | 20,000 | 100.10 | 2,002,000 |
| 2018-05-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,581 | 86.00 | 221,963 |
| 2018-05-15 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 85.90 | 858,970 |
| 2018-05-14 | Skyler Jay S (Director) | Sale | 30,000 | 88.00 | 2,640,000 |
| 2018-05-14 | Skyler Jay S (Director) | Option Ex | 30,000 | 4.58 | 137,400 |
| 2018-05-10 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 2,855 | 7.63 | 21,783 |
| 2018-05-09 | Leach Jacob Steven (SVP, Research & Development) | Sale | 8,745 | 84.77 | 741,331 |
| 2018-05-09 | Leach Jacob Steven (SVP, Research & Development) | Option Ex | 8,745 | 8.53 | 74,551 |
| 2018-05-09 | Sayer Kevin R (President & CEO) | Sale | 17,245 | 84.37 | 1,454,995 |
| 2018-05-09 | Sayer Kevin R (President & CEO) | Option Ex | 31,464 | 7.63 | 240,070 |
| 2018-05-08 | Leach Jacob Steven (SVP, Research & Development) | Sale | 4,423 | 85.05 | 376,184 |
| 2018-05-08 | Leach Jacob Steven (SVP, Research & Development) | Option Ex | 1,923 | 3.19 | 6,134 |
| 2018-05-08 | Skyler Jay S (Director) | Sale | 31,464 | 85.11 | 2,678,026 |
| 2018-05-08 | Skyler Jay S (Director) | Option Ex | 31,464 | 7.63 | 240,070 |
| 2018-04-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,581 | 73.09 | 188,650 |
| 2018-04-16 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 73.04 | 730,410 |
| 2018-03-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 2,581 | 68.44 | 176,643 |
| 2018-03-15 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 65.51 | 655,120 |
| 2018-02-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,638 | 56.32 | 92,252 |
| 2018-02-15 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 55.91 | 559,100 |
| 2018-01-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 54.67 | 89,383 |
| 2018-01-16 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 56.86 | 568,590 |
| 2017-12-26 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 56.39 | 92,204 |
| 2017-12-12 | Sayer Kevin R (President & CEO) | Sale | 6,000 | 58.85 | 353,094 |
| 2017-12-11 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 3,245 | 61.23 | 198,691 |
| 2017-11-29 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 2,900 | 60.12 | 174,339 |
| 2017-11-29 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 6,490 | 60.00 | 389,400 |
| 2017-11-27 | Foletta Mark G (Director) | Sale | 2,500 | 54.95 | 137,385 |
| 2017-11-24 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 55.53 | 90,788 |
| 2017-11-20 | Kahn Barbara (Director) | Sale | 3,000 | 54.58 | 163,728 |
| 2017-11-20 | Sayer Kevin R (President & CEO) | Sale | 12,000 | 55.00 | 660,000 |
| 2017-11-07 | Altman Steven R (Director) | Buy | 25,000 | 50.01 | 1,250,250 |
| 2017-11-06 | Altman Steven R (Director) | Buy | 10,000 | 49.61 | 496,100 |
| 2017-10-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 44.82 | 73,274 |
| 2017-09-25 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 69.77 | 114,080 |
| 2017-09-25 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 1,450 | 69.81 | 101,218 |
| 2017-09-20 | Sayer Kevin R (President & CEO) | Sale | 6,000 | 69.34 | 416,045 |
| 2017-09-11 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 3,244 | 72.27 | 234,440 |
| 2017-08-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,635 | 75.26 | 123,053 |
| 2017-08-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 3,987 | 75.26 | 300,045 |
| 2017-08-11 | Sayer Kevin R (President & CEO) | Sale | 6,000 | 69.77 | 418,638 |
| 2017-08-10 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 3,244 | 71.18 | 230,920 |
| 2017-07-24 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 1,450 | 69.47 | 100,724 |
| 2017-07-12 | Sayer Kevin R (President & CEO) | Sale | 6,000 | 71.86 | 431,171 |
| 2017-07-10 | Balo Andrew K (EVP, Reg. Strategy, Clinical) | Sale | 3,200 | 71.55 | 228,972 |
| 2017-06-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,187 | 78.22 | 249,274 |
| 2017-06-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 1,450 | 78.19 | 113,376 |
| 2017-06-12 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 69.06 | 220,988 |
| 2017-06-12 | Sayer Kevin R (President & CEO) | Sale | 6,000 | 69.07 | 414,414 |
| 2017-05-24 | Gregg Terrance H (Executive Chairman) | Option Ex | 30,000 | 6.85 | 205,500 |
| 2017-05-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 68.29 | 217,289 |
| 2017-05-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 1,450 | 68.24 | 98,949 |
| 2017-05-17 | Sayer Kevin R (President & CEO) | Sale | 8,649 | 68.39 | 591,539 |
| 2017-05-17 | Sayer Kevin R (President & CEO) | Option Ex | 3,649 | 8.79 | 32,074 |
| 2017-05-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 71.93 | 230,176 |
| 2017-04-24 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 75.78 | 241,131 |
| 2017-04-24 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 1,450 | 75.89 | 110,040 |
| 2017-04-20 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 74.10 | 1,111,500 |
| 2017-04-17 | Sayer Kevin R (President & CEO) | Sale | 10,000 | 75.63 | 756,320 |
| 2017-04-17 | Sayer Kevin R (President & CEO) | Option Ex | 10,000 | 8.79 | 87,899 |
| 2017-04-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 78.19 | 250,208 |
| 2017-03-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 76.38 | 243,028 |
| 2017-03-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 3,987 | 76.25 | 304,004 |
| 2017-03-22 | Roper Jess (SVP, CFO) | Sale | 2,000 | 75.97 | 151,936 |
| 2017-03-17 | Sayer Kevin R (President & CEO) | Sale | 10,000 | 77.82 | 778,160 |
| 2017-03-17 | Sayer Kevin R (President & CEO) | Option Ex | 10,000 | 8.79 | 87,899 |
| 2017-03-14 | Leach Jacob Steven (SVP, Research & Development) | Sale | 3,050 | 77.32 | 235,825 |
| 2017-03-14 | Kahn Barbara (Director) | Sale | 3,000 | 77.36 | 232,080 |
| 2017-03-13 | Leach Jacob Steven (SVP, Research & Development) | Sale | 7,926 | 77.92 | 617,625 |
| 2017-03-13 | Valdes Jorge A (CTO) | Sale | 14,400 | 77.74 | 1,119,513 |
| 2017-03-10 | Leach Jacob Steven (SVP, Research & Development) | Option Ex | 7,500 | 7.63 | 57,225 |
| 2017-03-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 77.71 | 248,671 |
| 2017-03-09 | Leach Jacob Steven (SVP, Research & Development) | Sale | 10,341 | 77.40 | 800,383 |
| 2017-03-09 | Lister John (General Manager, EMEA) | Sale | 3,000 | 77.67 | 233,001 |
| 2017-03-09 | Lister John (General Manager, EMEA) | Option Ex | 3,000 | 8.85 | 26,550 |
| 2017-03-06 | Skyler Jay S (Director) | Sale | 31,890 | 78.13 | 2,491,565 |
| 2017-03-06 | Skyler Jay S (Director) | Option Ex | 31,890 | 7.31 | 233,115 |
| 2017-02-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 78.42 | 249,529 |
| 2017-02-22 | Roper Jess (SVP, CFO) | Sale | 2,333 | 78.77 | 183,758 |
| 2017-02-17 | Sayer Kevin R (President & CEO) | Sale | 10,000 | 81.62 | 816,180 |
| 2017-02-17 | Sayer Kevin R (President & CEO) | Option Ex | 10,000 | 8.79 | 87,899 |
| 2017-02-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 79.30 | 253,760 |
| 2017-02-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 727 | 9.80 | 7,124 |
| 2017-02-09 | Lister John (General Manager, EMEA) | Sale | 3,000 | 79.73 | 239,205 |
| 2017-02-09 | Lister John (General Manager, EMEA) | Option Ex | 3,000 | 8.85 | 26,550 |
| 2017-02-09 | Valdes Jorge A (CTO) | Sale | 7,000 | 79.76 | 558,313 |
| 2017-02-09 | Valdes Jorge A (CTO) | Option Ex | 7,000 | 9.80 | 68,600 |
| 2017-02-01 | Valdes Jorge A (CTO) | Sale | 13,900 | 80.00 | 1,112,000 |
| 2017-02-01 | Valdes Jorge A (CTO) | Option Ex | 13,900 | 9.80 | 136,220 |
| 2017-01-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 79.50 | 252,978 |
| 2017-01-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 9,637 | 80.00 | 770,911 |
| 2017-01-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 9,637 | 7.79 | 75,072 |
| 2017-01-18 | Roper Jess (SVP, CFO) | Sale | 3,012 | 85.01 | 256,050 |
| 2017-01-17 | Sayer Kevin R (President & CEO) | Sale | 10,000 | 85.94 | 859,360 |
| 2017-01-17 | Sayer Kevin R (President & CEO) | Option Ex | 10,000 | 8.79 | 87,899 |
| 2017-01-13 | Lister John (General Manager, EMEA) | Sale | 15,000 | 79.36 | 1,190,400 |
| 2017-01-13 | Lister John (General Manager, EMEA) | Option Ex | 15,000 | 8.85 | 132,750 |
| 2017-01-13 | Valdes Jorge A (CTO) | Sale | 26,100 | 80.00 | 2,088,000 |
| 2017-01-13 | Valdes Jorge A (CTO) | Option Ex | 26,100 | 9.08 | 236,909 |
| 2017-01-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 3,200 | 62.86 | 201,152 |
| 2017-01-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 3,200 | 9.80 | 31,360 |
| 2017-01-09 | Lister John (General Manager, EMEA) | Sale | 3,000 | 63.02 | 189,045 |
| 2017-01-09 | Lister John (General Manager, EMEA) | Option Ex | 3,000 | 8.85 | 26,550 |
| 2017-01-09 | Valdes Jorge A (CTO) | Sale | 10,900 | 63.16 | 688,476 |
| 2017-01-09 | Valdes Jorge A (CTO) | Option Ex | 10,900 | 6.56 | 71,504 |
| 2016-12-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 62.17 | 197,831 |
| 2016-12-14 | Roper Jess (SVP, CFO) | Sale | 2,442 | 64.14 | 156,620 |
| 2016-12-09 | Valdes Jorge A (CTO) | Sale | 10,000 | 64.81 | 648,080 |
| 2016-12-09 | Valdes Jorge A (CTO) | Option Ex | 10,000 | 7.61 | 76,100 |
| 2016-11-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 70.19 | 223,350 |
| 2016-11-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 70.32 | 724,265 |
| 2016-11-09 | Lister John (General Manager, EMEA) | Sale | 3,417 | 62.50 | 213,562 |
| 2016-10-24 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 81.12 | 258,111 |
| 2016-10-24 | Roper Jess (SVP, CFO) | Sale | 2,471 | 80.75 | 199,545 |
| 2016-10-24 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 81.95 | 844,064 |
| 2016-10-19 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 4,997 | 82.31 | 411,303 |
| 2016-10-14 | Sayer Kevin R (President & CEO) | Sale | 7,000 | 81.87 | 573,104 |
| 2016-10-10 | Lister John (General Manager, EMEA) | Sale | 3,560 | 84.41 | 300,506 |
| 2016-10-10 | Valdes Jorge A (CTO) | Sale | 11,000 | 84.42 | 928,576 |
Insider trading activities including stock purchases, stock sales, and option exercises of DXCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dexcom Inc (symbol DXCM, CIK number 1093557) see the Securities and Exchange Commission (SEC) website.